Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Leaf Huang, Jonathan Kaufman and Michael Chancellor in 2005 and is headquartered in Pittsburgh, PA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

PITTSBURGH, November 21, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results.

PITTSBURGH, November 12, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S.

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware.

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

PITTSBURGH, PA, October 15, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform.

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

PITTSBURGH, Oct. 09, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO).

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP).

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C.

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Pittsburgh, PA, August 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals (NASDAQ: LIPO ) stock is flying higher on Monday after the company presented investors with an update on its Phase 2a clinical trial evaluating LP-310. This is the company's drug candidate for the treatment of Oral Lichen Planus ( OLP ).

Why Is Lipella Pharmaceuticals (LIPO) Stock Up 149% Today?

Top Line Data Expected Year-End 2024 Pittsburgh, July 29, 2024 — Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Clinical testing of LP-310 expected to commence in mid-2024    Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, PA., May 31, 2024 — Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration (“FDA”) Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program.

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA Pittsburgh, PA, April 17, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise.

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Pittsburgh, PA, April 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois.

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Pittsburgh, PA, April 03, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S.

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S.

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company's lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”) a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr.

News for Lipella Pharmaceuticals Inc Stock (LIPO)